Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sabinsa Gains Novel Food Approval for Curcumin C3 Reduct from EFSA - Nutraceuticals World
Market Updates, Products & Ingredients, Regulations

Sabinsa Gains Novel Food Approval for Curcumin C3 Reduct from EFSA

The regulatory status paves the way for sale in the E.U.

Opening the door to sale in the E.U., the European Food Safety Authority (EFSA) has granted Novel Food approval to Sabinsa for the company’s patented Curcumin C3 Reduct, which contains the curcuminoid metabolites tetrahydrocurcuminoids (THCs).

Sabinsa says its C3 Reduct overcomes bioavailability limitations of curcumin through its metabolites, particularly the reduced form of THCs, which confer essentially the same benefits of parent curcuminoids. Curcuminoids exert their effects through gastrointestinal as well as systemic routes, Sabinsa noted. 

Research has demonstrated that C3 Reduct is a potent antioxidant, and that THCs exhibit anti-inflammatory activity. THCs have also been explored for colonic health.

“Gut resident bacteria also metabolize curcumin to THC, thus explaining many of the benefits that are ascribable to curcuminoids,” said Dr. Muhammed Majeed, founder and chairman of Sami-Sabinsa Group. “The benefits are comprehensively described in a recent monograph Sabinsa has published. Incidentally C3 Reduct is a fitting solution to the perceived limited systemic bioavailability of curcumin. I commend our technical and commercial teams that worked hard to reach this milestone.” 

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters